PubMed Health⌕ Search

Biomedical subjects

Oral Nevruz

Publications and source records attributed to Oral Nevruz.

13 recordsLinked to original sources
PubMed2007

Cognitive dysfunction in beta-thalassemia minor.

Beta-thalassemia minor is a common, hereditary, and mostly symptomless disease. Previous studies have shown that lower hemoglobin values are associated with poorer cognitive functions. We aimed to evaluate the cognitive function in patients with beta-thalassemia minor. Thirty-two male subjects with beta-thalassemia minor and 32 sex-, age-, and education status-matched healthy subjects were enrolled in the study. Blood tests and P300 potentials were carried out. P300 potential latency in all patients was significantly longer than those in the control group (337.63+/-34.89 msec and 310.66+/-14.30 msec, respectively; t 4.046, P<0.001). The amplitudes of P300 in patient group were significantly lower than those in the control group (5.19+/-3.59 microV and 9.81+/-3.33 microV, respectively; t 5.349, P<0.001). In this study, we have found that P300 potentials are adversely affected for cognitive functions in patients with beta-thalassemia minor.

Adolescent↗
PubMed2006

Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases.

Adiponectin, an adipocyte-secreted hormone, is an important negative regulator in the immune system and hematopoiesis. In this study, we investigated the association of adiponectin levels with chronic lymphocytic leukemia (CLL) and myeloproliferative diseases (MPDs). We measured adiponectin levels in 19 patients with CLL and 30 patients with MPD (chronic myelogenous leukemia, 15; polycythemia vera, 9; myelofibrosis, 4; essential thrombocythemia, 2). The data were (chronic myelogenous leukemia, 15; polycythemia vera, 9; myelofibrosis, 4; essential thrombocythemia, 2). The data were compared with results from a control group of healthy volunteers who were matched according to age, sex, and body mass index. The adiponectin levels in patients with CLL were lower than in the controls (4.71 +/- 1.33 microg/mL versus 16.61 +/- 3.91 microg/mL; P <.001). They were also significantly lower in patients with MPD than in the controls (8.95 +/- 1.33 microg/mL versus 16.16 +/- 4.77 microg/mL; P <.001). In addition, we compared the adiponectin levels of MPD patients who were treated with interferon (IFN) to the levels of patients who were not treated with IFN. Adipnectin levels were significantly higher in IFN-treated patients (11.03 +/- 1.39 microg/mL versus 6.87 +/- 1.79 microg/mL; P <.001). These results suggest that lymphopoiesis and myelopoiesis negatively influence adiponectin levels. Adiponectin may be related to inflammatory cytokine release. IFN therapy appears to have a positive influence on adiponectin secretion by suppressing inflammatory cytokines. Future studies are needed to prove causality and to provide insight about this hormone's mechanism of action and its potential role regarding the etiology and progression of CLL and MPD.

Adiponectin↗
PubMed2005

Evaluation of platelet parameters in healthy apheresis donors using the ADVIA 120.

Platelet apheresis is accepted as a safe procedure and no clinically important change is observed after apheresis. The ADVIA 120 provides both an accurate platelet count and parameters describing platelet morphology and function. We studied the changes in platelet parameters of 35 healthy apheresis donors using the ADVIA 120. The mean platelet component value did not change after apheresis but the value of the platelet count was low and this reduction could be due to activation of platelets. We conclude that no remarkable changes were noted except the reduction in platelet numbers and plateletcrit which were expected to return to normal values in a few days.

Blood Donors↗
PubMed2005

Leucopenia and thrombocytopenia possibly associated with lamotrigine use in a patient.

Haematological side effects are rather exceptional with lamotrigine. We report the case of a 25-year-old woman with epilepsy who developed combined leucopenia and thrombocytopenia eight weeks after starting lamotrigine. Within weeks after lamotrigine was discontinued, all of the haematopoietic abnormalities had disappeared. To our knowledge, this is the first report of combined leucopenia and thrombocytopenia associated with lamotrigine treatment suggesting, in our patient, a causal reaction.

Adult↗
PubMed2004

Outer hair cell activity of the cochlea in patients with iron deficiency anemia.

OBJECTIVE: Iron deficiency anemia is a common disorder, which has been reported to affect the auditory system. However, there are some conflicting points related with the pattern of hearing impairment. The aim of this study is to analyze the outer hair cell activity of the cochlea in patients with iron deficiency anemia. METHOD: Pure-tone audiometry (PTA) (250-6000 Hz) and distortion product otoacoustic emission (DPOAE) results of 42 patients with iron deficiency anemia and 22 healthy, age and sex matched subjects for the control group were compared. Cubic DPOAEs (2f1-f2) were obtained at 65 and 55 dB sound pressure level (SPL). DP grams were plotted as a function of f2 and signal-to-noise ratio (SNR) was specified as the difference in decibels SPL between DPOAE amplitude and the ambient noise level at a given f2. In DP grams, DP amplitudes and noise levels obtained from the baseline measurements were presented as the upper and lower limits of DP amplitude and noise level that were the 10th and 90th percentiles calculated by adding and subtracting standard deviations and from mean baseline DP amplitude and noise level. Independent-samples t-test is used for comparison of the groups. RESULTS: Pure-tone audiometry was normal in patients with iron deficiency anemia and control subjects and there was no significant difference in comparison of DPOAE in both groups and both sides and the results were between two percentiles (P > 0.05). CONCLUSION: The results of the present study did not support a casual relationship between the iron deficiency anemia and the auditory dysfunction on the basis of DPOAE.

Adult↗
PubMed2003

The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.

Bisphosphonates have recently been introduced in the therapeutic armamentarium for long-term treatment of patients with multiple myeloma. These pyrophosphate analogs not only reduce the occurrence of skeletal events but also provide clinical benefit to patients and improve the survival of some of them. The existence of these capabilities raises the possibility that these compounds may have a direct antiproliferative effect on tumor cells. To investigate whether these drugs exert a direct antitumor effect, we exposed human myeloma cell lines ARH-77 and RPMI-8226 to increasing concentrations of zoledronic acid (ZOL) in vitro. A concentration- but not time-dependent cytotoxic effect was detected with drug treatment of ARH-77 and RPMI-8226 cell lines (30% and 60% at 48 hours and 38% and 62% at 72 hours, respectively, for 50 microM of ZOL). Cytotoxicity was not due to ZOL-induced chelation of extracellular calcium as shown by control experiments with the calcium chelator ethylene glycol-bis(beta-aminoethylether)-N,N,N',N'-tetraacetic acid. Addition of the competitive inhibitor of the nitric oxide synthase N omega-nitro-L-arginine methyl ester did not modulate ZOL-induced cytotoxicity. However, a decrease in the number of apoptotic cells was detected when protein kinase C was inhibited by addition of staurosporine to ZOL-containing cultures. Cytotoxicity also was increased by addition of dexamethasone (Dex) and thalidomide (Thal) to ARH-77 and RPMI-8226 cultures. We demonstrated that exposing myeloma cell lines ARH-77 and RPMI-8226 to ZOL inhibits cell growth in a dose-dependent but not a time-dependent manner and that combination of Dex and Thal with ZOL induces apoptotic cell death, providing a rationale for potential applications in vivo.

Antineoplastic Agents↗
PubMed2003

Effect of plateletpheresis on complete blood count values using three different cell separator systems in healthy donors.

The aim of this study is to investigate changes of CBC values after plateletpheresis in healthy and volunteer donors by using three different cell separator systems. The platelets were collected from 95 donors using the COBE Spectra, from 87 donors using the Fenwal CS-3000 Plus, and from 83 donors using the Fresenius AS-204. After plateletpheresis, white blood cells (WBC), hemoglobin (HGB), hematocrit (HCT), and platelets (PLT) were decreased significantly. When we used the COBE Spectra, the drop in the values of HGB and HCT was significantly less than for the other devices. It is recommended that hematological parameters should be monitored carefully in donors who are supposed to undergo long-term regular apheresis, and to prevent the occurrence of an artificial anemia, which is likely to happen. Selection of cell separator systems should be based on this possibility.

Blood Cell Count↗
PubMed2002

Facial paresis after fludarabine treatment for advanced chronic lymphocytic leukaemia.

This case report discusses a case with advanced-stage chronic lymphocytic leukaemia (CLL) that presented with facial paresis after fludarabine treatment. A 68-year old patient with CLL (Rai classification, stage IV) was admitted to Gülhane Military Medical Academy for treatment. Fludarabine, 30 mg/m2 daily for 5 days, was given. Right facial paresis was observed at day 8 after administration of fludarabine. The general and psychiatric condition of the patient in myelosuppression did not permit aetiological investigation for paresis. Thereafter, the patient died due to septic shock. Possible aetiological reasons why the patient being treated for advanced-stage CLL had facial paresis after the administration of fludarabine ended are discussed.

Aged↗
PubMed2002

Severe hyperglycemia as a complication of big ICE chemotherapy in a patient with acute myeloblastic leukemia.

BACKGROUND: Big ICE chemotherapy (consisting of Idarubicin, high dose Cytosine arabinoside and Etoposide), has proven its efficacy in the treatment of patients with relapse/refractory acute myeloblastic leukemia. In this case report, we present a patient developing the complication of severe hyperglycemia following administration of big ICE because of a relapse of acute myeloblastic leukemia. CASE REPORT: When a 41-year-old woman with acute myeloblastic leukemia in relapse was treated using the big ICE protocol, because of lack of efficacy of other chemotherapy regimens. On the 7th day and 9th day of chemotherapy, glycemia was 13.2 mmol/l and 25.8 mmol/l, respectively. Hyperglycemia was controlled with continuous regular insulin infusion and neutralization of parenteral nutrition solution with regular insulin. After the regulation of the glycemia, regular insulin was injected four times daily. Following days, hematological remission was obtained and requirement of insulin becomes less and glycemia decreased to the normal levels. CONCLUSION: Severe hyperglycemia/diabetes mellitus likely due to chemotherapy may develop in patients with acute leukemia. This may have a negative effect on mortality and morbidity. For this reason, these patients should be followed closely.

Adult↗